278 related articles for article (PubMed ID: 27783999)
1. Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma.
Xiong Y; Liu L; Wang J; Xi W; Xia Y; Bai Q; Qu Y; Long Q; Xu J; Guo J
Oncotarget; 2017 Apr; 8(15):25650-25659. PubMed ID: 27783999
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
Xia Y; Liu L; Xiong Y; Bai Q; Wang J; Xi W; Qu Y; Xu J; Guo J
BMC Cancer; 2017 Jan; 17(1):70. PubMed ID: 28114889
[TBL] [Abstract][Full Text] [Related]
3. Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma.
Xiong Y; Liu L; Xia Y; Wang J; Xi W; Bai Q; Qu Y; Xu J; Guo J
BMC Cancer; 2017 Feb; 17(1):117. PubMed ID: 28178948
[TBL] [Abstract][Full Text] [Related]
4. CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma.
Wang Z; Xie H; Zhou L; Liu Z; Fu H; Zhu Y; Xu L; Xu J
Oncotarget; 2016 Aug; 7(32):51525-51534. PubMed ID: 27409666
[TBL] [Abstract][Full Text] [Related]
5. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
[TBL] [Abstract][Full Text] [Related]
6. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Laba P; Wang J; Zhang J
BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
[TBL] [Abstract][Full Text] [Related]
7. High Expression of Stearoyl-CoA Desaturase 1 Predicts Poor Prognosis in Patients with Clear-Cell Renal Cell Carcinoma.
Wang J; Xu Y; Zhu L; Zou Y; Kong W; Dong B; Huang J; Chen Y; Xue W; Huang Y; Zhang J
PLoS One; 2016; 11(11):e0166231. PubMed ID: 27861513
[TBL] [Abstract][Full Text] [Related]
8. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
9. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma.
An H; Xu L; Chang Y; Zhu Y; Yang Y; Chen L; Lin Z; Xu J
Eur J Cancer; 2015 Sep; 51(14):1953-61. PubMed ID: 26188847
[TBL] [Abstract][Full Text] [Related]
10. IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma.
Bai Q; Liu L; Xia Y; Wang J; Xi W; Qu Y; Xiong Y; Long Q; Xu J; Guo J
Oncotarget; 2017 Jul; 8(27):44186-44194. PubMed ID: 28562332
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of UTX expression in patients with clear cell renal cell carcinoma.
Wang J; Liu L; Xi W; Long Q; Wang Y; Bai Q; Xia Y; Xu J; Guo J
Urol Oncol; 2016 Aug; 34(8):338.e19-27. PubMed ID: 27106782
[TBL] [Abstract][Full Text] [Related]
12. High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma.
Liu Y; Yang L; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
Sci Rep; 2015 Nov; 5():16954. PubMed ID: 26599282
[TBL] [Abstract][Full Text] [Related]
13. Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Merseburger AS; Hennenlotter J; Kuehs U; Simon P; Kruck S; Koch E; Stenzl A; Kuczyk MA
Urol Int; 2008; 80(4):372-7. PubMed ID: 18587247
[TBL] [Abstract][Full Text] [Related]
14. Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma.
Xie H; Zhu Y; An H; Wang H; Zhu Y; Fu H; Wang Z; Fu Q; Xu J; Ye D
Oncotarget; 2016 May; 7(22):32723-30. PubMed ID: 27092876
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma.
Zhang X; Yin X; Zhang H; Sun G; Yang Y; Chen J; Shu K; Zhao J; Zhao P; Chen N; Wang J; Shen P; Zeng H
BMC Cancer; 2019 Jan; 19(1):49. PubMed ID: 30630458
[TBL] [Abstract][Full Text] [Related]
16. High CLEC-2 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma.
Xiong Y; Liu L; Xia Y; Wang J; Xi W; Bai Q; Qu Y; Long Q; Xu J; Guo J
Oncotarget; 2016 Sep; 7(39):63661-63668. PubMed ID: 27564117
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of mucin 18 is associated with unfavorable postoperative prognosis in patients with clear cell renal cell carcinoma.
Bai Q; Liu L; Long Q; Xia Y; Wang J; Xu J; Guo J
Int J Clin Exp Pathol; 2015; 8(9):11005-14. PubMed ID: 26617818
[TBL] [Abstract][Full Text] [Related]
18. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
[TBL] [Abstract][Full Text] [Related]
19. High expression of chemokine CCL2 is associated with recurrence after surgery in clear-cell renal cell carcinoma.
Yang Y; Zhai C; Chang Y; Zhou L; Shi T; Tan C; Xu L; Xu J
Urol Oncol; 2016 May; 34(5):238.e19-26. PubMed ID: 26749463
[TBL] [Abstract][Full Text] [Related]
20. Glycoprotein non-metastatic melanoma protein B as a predictive prognostic factor in clear-cell renal cell carcinoma following radical nephrectomy.
Qin C; Liu Z; Yuan Y; Zhang X; Li H; Zhang C; Xu T; Wang X
Mol Med Rep; 2014 Mar; 9(3):851-6. PubMed ID: 24425288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
